Clinical Trial Update: A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy [Phase 2]

View source ↗

Summary

Phase 2 trial of CAP-1002 in ambulatory and non-ambulatory Duchenne muscular dystrophy completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• CAP-1002 (cardiosphere-derived cells)

Snippet

Sponsor: Capricor Inc. | Conditions: Muscular Dystrophies, Muscular Dystrophy, Duchenne | Phase 2 | Status: COMPLETED | Results posted: 2025-02-24